CAS 1429505-03-2

Soticlestat

Description:

Soticlestat, with the CAS number 1429505-03-2, is a novel chemical compound primarily recognized for its role as a selective inhibitor of the enzyme cholesterol 24-hydroxylase (CYP46A1). This enzyme is crucial in the metabolism of cholesterol in the brain, and its inhibition is being explored for potential therapeutic applications in neurodegenerative diseases, particularly in conditions like Alzheimer's disease. Soticlestat's mechanism of action involves modulating cholesterol levels and influencing neuroinflammation, which may contribute to its neuroprotective effects. The compound is characterized by its specific binding affinity to the target enzyme, which allows for a reduction in the production of neurotoxic metabolites derived from cholesterol. Additionally, Soticlestat is being studied for its pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME), to evaluate its suitability for clinical use. As research continues, Soticlestat's safety profile and efficacy in human subjects will be critical in determining its potential as a therapeutic agent in neurology.

Formula: C₂₃H₂₃N₃O₂

Synonyms:

• Soticlestat
• TAK-935
• OV935
• Methanone, [2,4'-bipyridin]-3-yl[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-

Soticlestat

CAS: 1429505-03-2

Soticlestat

Purity: ≥98%

Molecular weight: 373.45g/mol

Ref: 54-BUP03637

Soticlestat

CAS: 1429505-03-2

Soticlestat (OV935) is a potent, selective and orally active cholesterol 24-hydroxylase (CYP46A1) inhibitor.

Formula: C₂₃H₂₃N₃O₂

Purity: 99.79%

Color and Shape: Solid

Molecular weight: 373.45

Ref: TM-T8937

Soticlestat

CAS: 1429505-03-2

Soticlestat is an investigational pharmaceutical compound that functions as a selective inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). This enzyme is predominantly found in the brain, where it catalyzes the conversion of cholesterol to 24S-hydroxycholesterol, a process implicated in neuroinflammation and excitotoxicity. By inhibiting CH24H, Soticlestat aims to reduce the overproduction of 24S-hydroxycholesterol, which is associated with various neurological disorders.The primary source of Soticlestat is synthetic chemical development, characterized by the precision in targeting specific enzymatic processes within the central nervous system. The compound's mode of action involves binding to CH24H, leading to decreased activity of this enzyme and thus reducing downstream neurotoxic effects that can exacerbate conditions such as epilepsy and developmental epileptic encephalopathies.Soticlestat is currently being investigated for its potential therapeutic applications in managing treatment-resistant epilepsy and certain rare pediatric epileptic conditions. By modulating cholesterol metabolism in the brain, it holds the promise of offering new insights and approaches for mitigating neurological dysfunction, ultimately aiming to provide better outcomes for patients with limited treatment options.

Formula: C₂₃H₂₃N₃O₂

Purity: Min. 95%

Molecular weight: 373.4 g/mol

Ref: 3D-EHC50503